New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
05:27 EDTAGEN, GSKGlaxo's Phase 3 Malaria Vaccine Candidate with Agenus' QS-21 shows efficacy
Agenus (AGEN) announced the second complete set of results from the Phase 3 trial of GlaxoSmithKline's (GSK) RTS,S malaria vaccine candidate -- also known as Mosquirix -- which contains Agenus' QS-21 Stimulon adjuvant, were published online in the New England Journal of Medicine and announced at the International Vaccines for Africa Conference in Cape Town, South Africa. QS-21 Stimulon is a component of AS01, one of GSK's proprietary adjuvant systems used in RTS,S. The Phase 3 study met its primary endpoint and demonstrates statistically significant protection against clinical and severe malaria in infants. Agenus is entitled to receive milestone payments as QS-21-containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions.
News For AGEN;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
07:11 EDTGSK, AGENAgenus: GSK's RTS,S vaccine showed statistically significant results in study
Subscribe for More Information
April 23, 2015
07:03 EDTAGENAgenus reports Q1 EPS (28c), may not compare to consensus (1c)
Reports Q1 revenue $3.95M, may not compare to consensus $11.66M.
April 22, 2015
14:56 EDTAGENAgenus management to meet with William Blair
Meeting to be held in Philadelphia on April 27 hosted by William Blair.
April 20, 2015
07:20 EDTGSKAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:01 EDTGSKPernix Therapeutics obtains six months U.S. pediatric exclusivity for Treximet
Subscribe for More Information
April 16, 2015
09:14 EDTGSKAdamis says albuterol HFA product study met clinical FEV1 primary endpoint
Subscribe for More Information
08:15 EDTGSKGlaxoSmithKline and Theravance announce launch of Anoro in Spain
In a regulatory filing, GlaxoSmithKline (GSK) and Theravance (THRX) announced the launch of Anoro in Spain following the approval in Europe in May 2014. Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Anoro Ellipta is a combination of two bronchodilators, umeclidinium, a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, in a single dry powder inhaler, the Ellipta. The approved dose of UMEC/VI is 55/22mcg. UMEC/VI has been developed under the 2002 LABA collaboration agreement between Glaxo Group Limited and Theravance.
April 15, 2015
11:53 EDTGSKGlaxoSmithKline initiated with a Sell at Societe Generale
07:41 EDTAGENEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use